IN2014DN09830A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN09830A IN2014DN09830A IN9830DEN2014A IN2014DN09830A IN 2014DN09830 A IN2014DN09830 A IN 2014DN09830A IN 9830DEN2014 A IN9830DEN2014 A IN 9830DEN2014A IN 2014DN09830 A IN2014DN09830 A IN 2014DN09830A
- Authority
- IN
- India
- Prior art keywords
- formula
- vivo
- exhibits
- correction
- enabling
- Prior art date
Links
- 0 CC1=C(CCC[C@]2(CC*)[C@](CCCCC3C(CC4CC4)C3)CCC2)CCC1 Chemical compound CC1=C(CCC[C@]2(CC*)[C@](CCCCC3C(CC4CC4)C3)CCC2)CCC1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A water- soluble compound of the formula (I): (Formula (I)) wherein R9 and R10 are suitably hydrophilic substituents which may be used to selectively bind to a target saccharide such as glucose and which exhibits a detectable spectroscopic response to such binding, thus enabling its use in the detection and correction of blood glucose concentrations in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1207392.0A GB201207392D0 (en) | 2012-04-27 | 2012-04-27 | Novel compounds |
PCT/GB2013/051079 WO2013160701A1 (en) | 2012-04-27 | 2013-04-26 | Anthracenyl - tetralactam macrocycles and their use in detecting a target saccharide |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN09830A true IN2014DN09830A (en) | 2015-08-07 |
Family
ID=46330449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN9830DEN2014 IN2014DN09830A (en) | 2012-04-27 | 2013-04-26 |
Country Status (9)
Country | Link |
---|---|
US (2) | US9610365B2 (en) |
EP (1) | EP2855439B1 (en) |
CN (1) | CN104428290B (en) |
AU (1) | AU2013254450A1 (en) |
CA (1) | CA2910581A1 (en) |
GB (2) | GB201207392D0 (en) |
HK (1) | HK1209112A1 (en) |
IN (1) | IN2014DN09830A (en) |
WO (1) | WO2013160701A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201207392D0 (en) | 2012-04-27 | 2012-06-13 | Univ Bristol | Novel compounds |
EP3596055A1 (en) * | 2017-03-15 | 2020-01-22 | Ziylo Limited | Macrocyclic compounds |
US11541122B2 (en) | 2018-09-19 | 2023-01-03 | Ziylo Limited | Glucose sensitive insulins and uses thereof |
WO2021021120A1 (en) * | 2019-07-30 | 2021-02-04 | Emd Millipore Corporation | Method of synthesizing chemical compounds |
RU2752711C2 (en) * | 2019-11-18 | 2021-07-30 | Общество с ограниченной ответственностью «Лаборатория межклеточных технологий «Интерсел Рэнд» (ООО «Интерсел Рэнд») | Method and device for spectroscopy of living tissue |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003535122A (en) * | 2000-06-02 | 2003-11-25 | ザイコス インク. | Delivery system for bioactive substances |
JP2003073399A (en) * | 2001-08-31 | 2003-03-12 | Japan Science & Technology Corp | Fluorescence-emitting modified protein |
US7179616B1 (en) | 2002-10-07 | 2007-02-20 | University Of Notre Dame Du Lac | Method for detecting phosphatidylserine on the surface of cells |
US8642014B2 (en) * | 2007-01-30 | 2014-02-04 | Seta Biomedicals, Llc | Luminescent compounds |
WO2011059457A1 (en) * | 2009-11-16 | 2011-05-19 | University Of Notre Dame Du Lac | High performance luminescent compounds |
US20120296085A1 (en) * | 2010-01-13 | 2012-11-22 | University Of Notre Dame Du Lac | Chemiluminescent dyes and dye-stained particles |
GB201207392D0 (en) | 2012-04-27 | 2012-06-13 | Univ Bristol | Novel compounds |
-
2012
- 2012-04-27 GB GBGB1207392.0A patent/GB201207392D0/en not_active Ceased
-
2013
- 2013-04-26 CA CA2910581A patent/CA2910581A1/en not_active Abandoned
- 2013-04-26 US US14/397,254 patent/US9610365B2/en not_active Expired - Fee Related
- 2013-04-26 IN IN9830DEN2014 patent/IN2014DN09830A/en unknown
- 2013-04-26 AU AU2013254450A patent/AU2013254450A1/en not_active Abandoned
- 2013-04-26 GB GB1420937.3A patent/GB2517345A/en not_active Withdrawn
- 2013-04-26 CN CN201380034334.4A patent/CN104428290B/en not_active Expired - Fee Related
- 2013-04-26 EP EP13727309.0A patent/EP2855439B1/en not_active Not-in-force
- 2013-04-26 WO PCT/GB2013/051079 patent/WO2013160701A1/en active Application Filing
-
2015
- 2015-10-07 HK HK15109782.6A patent/HK1209112A1/en unknown
-
2017
- 2017-02-28 US US15/445,710 patent/US9937272B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2855439A1 (en) | 2015-04-08 |
US9610365B2 (en) | 2017-04-04 |
GB201420937D0 (en) | 2015-01-07 |
AU2013254450A1 (en) | 2014-11-27 |
GB2517345A (en) | 2015-02-18 |
HK1209112A1 (en) | 2016-03-24 |
WO2013160701A1 (en) | 2013-10-31 |
CN104428290A (en) | 2015-03-18 |
US20170266321A1 (en) | 2017-09-21 |
CN104428290B (en) | 2017-11-14 |
CA2910581A1 (en) | 2013-10-31 |
EP2855439B1 (en) | 2017-06-14 |
US20150147275A1 (en) | 2015-05-28 |
GB201207392D0 (en) | 2012-06-13 |
US9937272B2 (en) | 2018-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ597517A (en) | 5-fluoropyrimidinone derivatives | |
WO2014089209A3 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
MA32383B1 (en) | Indazole derivatives with phenyl and benzodoxynil alternatives | |
EA201591064A1 (en) | NEW PYRIDINE DERIVATIVES | |
MY156938A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
WO2012088266A3 (en) | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 | |
PH12012501905A1 (en) | Quinoline derivatives and their use as fungicides | |
EA201591527A1 (en) | NEW PYRIDINE DERIVATIVES | |
WO2013089882A3 (en) | Recurrent gene fusions in breast cancer | |
WO2012158780A3 (en) | Lung cancer signature | |
WO2015077635A8 (en) | Macromolecular antioxidants based on dual type moiety per molecule: structures methods of making and using the same | |
IN2015DN00636A (en) | ||
NZ597570A (en) | N1-acyl-5-fluoropyrimidinone derivatives | |
IN2014DN09830A (en) | ||
NI201100149A (en) | DERIVATIVES OF TIADIAZOLES AND OXADIAZOLES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY. | |
TR201909923T4 (en) | Composition containing the pyrazole derivative for the prevention or treatment of kidney disease. | |
WO2014039533A3 (en) | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin | |
MX342947B (en) | Treatment of type 2 diabetes. | |
MX349373B (en) | Novel pyrazine derivatives. | |
EA201270256A1 (en) | DERIVATIVES OF T1-SUBSTITUTED 5-FLUOR-2-OXOPYRIMIDINON-1 (2H) -KARBOXAMID | |
EA201100730A1 (en) | COMPLEX INCLUSION OF PINOCEMBRIN WITH CYCLODEXTRIN, METHOD FOR ITS PREPARATION AND APPLICATION | |
MX356126B (en) | Use of glutamide stabilizers. | |
TR201903918T4 (en) | Compositions containing a dispersing agent and their preparation. | |
MX2012010127A (en) | Derivatives of aminoindanes, their preparation and their application in therapeutics. | |
IN2014DN10669A (en) |